A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00496132
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG:
PRO131921
Sponsor
Genentech, Inc.